A61P 37 - Drugs for immunological or allergic disorders

Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
10/2001
10/11/2001	WO2001075072A2 PRODUCTION OF TcR GAMMA DELTA T CELLS
10/11/2001	WO2001075064A2 Method and materials relating to insulin-like growth factor binding protein-like polypeptides and polynucleotides
10/11/2001	WO2001074903A2 CD20/IgE-RECEPTOR LIKE MOLECULES AND USES THEREOF
10/11/2001	WO2001074900A2 Nuclear factor kb inducing factor
10/11/2001	WO2001074896A1 Human polynucleotides, polypeptides, and antibodies
10/11/2001	WO2001074894A1 A new polypeptide - human protein phosphatase 1 regulation protein 12 and the polynucleotide encoding it
10/11/2001	WO2001074856A2 Wnt-7b-like polypeptides and nucleic acids encoding same
10/11/2001	WO2001074855A2 Compositions and methods for dendritic cell-based immunotherapy
10/11/2001	WO2001074848A2 Immunodominant acetylcholine receptor alpha subunit peptides, complexes thereof with mhc class ii components and their use
10/11/2001	WO2001074811A2 Substituted 1,3-thiazole compounds, their production and use
10/11/2001	WO2001074806A1 Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain
10/11/2001	WO2001074801A1 Immunosuppressant n-acyles homoserine lactones
10/11/2001	WO2001074786A1 Heterobiarylsulphonamides and their use as pde 7 inhibitors
10/11/2001	WO2001074780A1 Chemical complex comprising a pyridine carboxy derivative and an h2 histamine receptor antagonist
10/11/2001	WO2001074769A1 Pharmaceutically active pyrrolidine derivatives as bax inhibitors
10/11/2001	WO2001074763A1 Aryl and heteroaryl sulfonates
10/11/2001	WO2001074506A1 Extrusion die
10/11/2001	WO2001074404A2 Compositions containing genetically modified lung cancer cells expressing a tgf-beta inhibitor
10/11/2001	WO2001074400A1 Transporters and drug delivery system by using the same
10/11/2001	WO2001074387A1 Use of aliphatic quaternary ammonium as adjuvant in a pharmaceutical composition administered by mucosal delivery
10/11/2001	WO2001074383A1 Chimeric antigen-enterotoxin mucosal immunogens
10/11/2001	WO2001074382A1 Method of treatment using ligand-immunogen conjugates
10/11/2001	WO2001074369A1 Divided dose therapies with vascular damaging activity
10/11/2001	WO2001074360A1 Therapeutic combinations of antihypertensive and antiangiogenic agents
10/11/2001	WO2001074128A2 A novel polypeptide, microtubulin 11 and the polynucleotide encoding the polypeptide
10/11/2001	WO2001066585A8 A new polypeptide-human protease regulatory protein 10 and the p olynucleotide encoding it
10/11/2001	WO2001049319A8 Composition containing bacterial antigens, used for the prophylaxis and the treatment of allergic diseases
10/11/2001	WO2001049317A3 Enhancing the immune response to an antigen by presensitizing with an inducing agent prior to immunizing with the inducing agent and the antigen
10/11/2001	WO2001036640A3 Human fgf-21 gene and gene expression products
10/11/2001	WO2001034572A3 Carboxamide-substituted benzimidazol derivatives, method for the production thereof and their use as tryptase inhibitors
10/11/2001	WO2001031003B1 Cloning, expression and characterisation of a gene expressed in tumour cells and involved in the regulation of the immune response
10/11/2001	WO2001025269A3 Human g-protein coupled receptor
10/11/2001	WO2001024763A3 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
10/11/2001	WO2001022956A3 NOVEL COMBINATION OF LOTEPREDNOL AND β2-ADRENOCEPTOR AGONISTS
10/11/2001	WO2001021202A3 Treatment of chronic inflammatory disease by inhibiting sub-groups of activated t-cells
10/11/2001	WO2001019826A3 Triazolopyrimidine derivatives
10/11/2001	WO2001012264A3 Topical azathioprine for the treatment of oral autoimmune diseases
10/11/2001	WO2001007625A3 Ehrlichia canis genes and vaccines
10/11/2001	WO2001007470A3 Human nervous system-associated proteins
10/11/2001	WO2000062736A3 Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) and surfactant depletion
10/11/2001	WO2000042429A3 In vitro model for gastrointestinal inflammation
10/11/2001	US20010029304 Cyclopentane heptan (ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
10/11/2001	US20010029250 Antiinflammatory agents; anticarcinogenic agents
10/11/2001	EP1145001A3 (in vitro) model for gastrointestinal inflammation
10/11/2001	DE10015866A1 Aryl- und Heteroarylsulfonate Aryl and Heteroarylsulfonate
10/11/2001	CA2405484A1 Immunodominant acetylcholine receptor alpha subunit peptides, complexes thereof with mhc class ii components and their use
10/11/2001	CA2405299A1 Method of treatment using ligand-immunogen conjugates
10/11/2001	CA2404576A1 Antagonist antibodies to ve-cadherin without adverse effects on vascular permeability
10/11/2001	CA2404545A1 Aryl and heteroaryl sulfonates
10/11/2001	CA2404519A1 Wnt-7b-like polypeptides and nucleic acids encoding same
10/11/2001	CA2404501A1 Method and materials relating to insulin-like growth factor binding protein-like polypeptides and polynucleotides
10/11/2001	CA2404384A1 Substituted 1,3-thiazole compounds, their production and use
10/11/2001	CA2404074A1 Human polynucleotides, polypeptides, and antibodies
10/11/2001	CA2403998A1 Mucin-1 specific binding members and methods of use thereof
10/11/2001	CA2403964A1 Compositions and methods for dendritic cell-based immunotherapy
10/11/2001	CA2403885A1 Chemical complex comprising a pyridine carboxy derivative and an h2 histamine receptor antagonist
10/11/2001	CA2403600A1 Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain
10/11/2001	CA2402078A1 Divided dose therapies with vascular damaging activity
10/11/2001	CA2401948A1 Cd20/ige-receptor like molecules and uses thereof
10/11/2001	CA2401854A1 Therapeutic combinations of antihypertensive and antiangiogenic agents
10/11/2001	CA2401137A1 Pharmaceutically active pyrrolidine derivatives as bax inhibitors
10/10/2001	EP1142910A1 Inhibitors for the formation of soluble human CD23
10/10/2001	EP1142903A1 BRAIN CELL OR NERVE CELL-PROTECTIVE AGENTS COMPRISING GINSENOSIDE Rb 1?
10/10/2001	EP1142890A1 Aminopyrazole derivatives
10/10/2001	EP1142889A1 Pyrazole derivatives as anti-inflammatory/analgesic agents
10/10/2001	EP1142877A1 2-oxoquinoline compounds and medicinal uses thereof
10/10/2001	EP1142875A1 Cinnamamide derivatives and drug compositions containing the same
10/10/2001	EP1142870A1 Novel ligands of nuclear receptor
10/10/2001	EP1142867A2 Cell adhesion inhibitors
10/10/2001	EP1142568A1 Pharmaceutical compositions containing cyclosporins
10/10/2001	EP1142566A1 Compositions for ophtalmic use containing cyclosporin, hyaluronic acid and polysorbate
10/10/2001	EP1142473A1 Method of acquiring immunological tolerance
10/10/2001	EP1141720A1 Detection of preactivated phagocytes
10/10/2001	EP1141376A1 Peptidoglycan recognition proteins
10/10/2001	EP1141364A1 Use of the cell's own transport system for transferring nucleic acids across the nuclear membrane
10/10/2001	EP1141342A2 Use of plus-strand synthesis elements in retroviral vectors
10/10/2001	EP1141332A1 Human cyclic nucleotide pdes
10/10/2001	EP1141325A1 Ikk3 kinase
10/10/2001	EP1141319A2 Extending graft survival by heme oxygenase-i expression induced immunomodulation
10/10/2001	EP1141315A2 Modified hiv env polypeptides
10/10/2001	EP1141314A2 Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
10/10/2001	EP1141313A2 Improved expression of hiv polypeptides and production of virus-like particles
10/10/2001	EP1141296A2 Interferon-epsilon
10/10/2001	EP1141290A2 Compositions and methods for therapy and diagnosis of ovarian cancer
10/10/2001	EP1141288A2 Lymphocytic membrane proteins
10/10/2001	EP1141286A1 Cytokine receptor chain
10/10/2001	EP1141278A2 Therapeutic phosphodiesterase inhibitors
10/10/2001	EP1141274A2 Soluble receptor br43x2 and methods of using them for therapy
10/10/2001	EP1141248A2 A METHOD FOR THE HIGH LEVEL EXPRESSION OF ACTIVE LYMPHOTOXIN-$g(b) RECEPTOR IMMUNOGLOBULIN CHIMERIC PROTEINS AND THEIR PURIFICATION
10/10/2001	EP1141246A2 Non-myeloablative tolerogenic treatment
10/10/2001	EP1141243A2 Methods of immunosuppression
10/10/2001	EP1141235A2 (bifidobacterium) in the treatment of inflammatory disease
10/10/2001	EP1141028A2 Human monoclonal antibodies to ctla-4
10/10/2001	EP1141027A1 Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
10/10/2001	EP1141024A2 Polypeptide variants with altered effector function
10/10/2001	EP1141023A2 Anti-cd3 immunotoxins and therapeutic uses therefor
10/10/2001	EP1141020A2 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof
10/10/2001	EP1141015A1 Insulin-like growth factor (igf) i mutant variants
10/10/2001	EP1141011A2 Compounds and methods to inhibit or augment an inflammatory response
10/10/2001	EP1141000A1 Superantigens

1 ... 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 ... 1172